Получена: 22.05.2023/ Принята: 06.12.2023/ Опубликована online: 29.12.2023
УДК 616. 12-921.5
DOI 10.53511/PHARMKAZ.2024.16.97.006
Г.К. НУРГАЛИЕВА1, С.Ж. УРАЗАЛИНА2, Н.И. ТОЛЕУОВА1, А.У. МЫРЗАБАЕВА1
1 Казахский Национальный Университет им. Аль-Фараби, Алматы, Республика Казахстан
2 НАО «Казахский Национальный Медицинский Университет им. С.Д. Асфендиярова» , Алматы, Республика Казахстан
CЕРДЕЧНО-СОСУДИСТАЯ СИСТЕМА И COVID-19 (ОБЗОР ЛИТЕРАТУРЫ)
Резюме. Коронавирусная болезнь 2019 (COVID-19) – это вирусная пандемия, вызванная тяжелым
острым респираторным синдромом, вызванным коронавирусом 2 (SARS-CoV-2). При этом сердечнососудистые осложнения у пациентов, страдающих новым респираторным заболеванием, вызванным коронавирусом (COVID-19), получают все большее признание. В данной статье проанализированы результаты публикаций последних лет, посвященных исследованиям особенностей функциональных и структурных нарушений сердечно-сосудистой системы, вызываемых COVID-19. В связи с
тем, что степень вовлеченности сердечно-сосудистой системы в инфекционный процесс является одним из основных факторов, влияющих на исход и выживаемость от данного заболевания, рекомендуется всем пациентам с лабораторно подтвержденной COVID-19 назначать: 1. Кардиологические методы исследования – ЭКГ, ЭхоКГ, суточное мониторирование ЭКГ; 2. Определение высокочувствительных кардиальных тропонинов, особенно в группах больных с различной сопутствующей патологией сердечно-сосудистой системы.
Ключевые слова: Ковид19, сердечно-сосудистая система, сердечно-сосудистые заболевания.
СПИСОК ЛИТЕРАТУРЫ
1 Wiersinga W. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19) // JAMA. – 2020. – №324. – S.782-793.
2 Soumya RS, Unni TG, Raghu KG. Impact of COVID-19 on the Cardiovascular System: A Review of Available Reports // Cardiovasc Drugs Ther. – 2021.-
№35(3).- S.411-425. doi: 10.1007/s10557-020- 07073- y. Epub 2020 Sep 14.
3 Баздырев Е.Д. Коронавирусная инфекция — актуальная проблема XXI века // Комплексные проблемы сердечно-сосудистых заболеваний. – 2020.
– № 9(2).- S. 6-16.
4 Bazdirev ED. Coronavirus infection –actual problem of 21century // Complex problems of cardio-vascular diseases. – 2020. – №9(2). – S.6-16.
5 Khawaja SA, Mohan P, Jabbour R, et al. COVID-19 and its impact on the cardiovascular system // Open Heart. – 2021. – №8 (e001472) doi: 10.1136/
openhrt-2020-001472.
6 Groß S, Jahn C, Cushman S, Bär C, Thum T. SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: from basic science to
clinical implications // J Mol Cell Cardiol. – 2020. – №144.- S.47–53.
7 Mohammad M, Safavi-Naeini P, Scott D et al. Potential Effects of Coronaviruses on the
Cardiovascular System // JAMA Cardiol. – 2020. – №5(7). – S.831-840.
8 Bojkova D, Wagner JUG, Shumliakivska M, Aslan GS et al. SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes // Cardiovasc Res.
– 2020.- №116(14). –S.2207-2215. doi:10.1093/cvr/cvaa267.
9 Sharma A, Garcia G Jr, Wang Y et al. Human iPSC-Derived Cardiomyocytes Are Susceptible to SARS-CoV-2 Infection //Cell Rep Med.–2020. – №21(4). –
S.100052. doi:10.1016/j.xcrm.2020.100052.
10 Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients
with COVID-19 in Wuhan, China // JAMA Cardiol. – 2020.- №25. –S.44-58.
11 Chen C, Yan JT et al. Analysis of myocardial injury in patients with COVID19 and association between concomitant cardiovascular diseases and severity
of COVID-19 // Zhonghua Xin Xue Guan
12 Bing Za Zhi. – 2020 . – №48: S.1020-1058.
13 Bansal M. Cardiovascular disease and COVID-19 // Diabetes Metab Syndr. – 2020. – №14. –S.247-250.
14 Bonow RO, Fonarow GC, O’Gara PT, Yancy CW. Association of coronavirus disease 2019 (COVID-19) with myocardial injury and mortality // JAMA Cardiol.
– 2020. – №5(7). – S.751-753. doi:10.1001/jamacardio.2020.1105.
15 Divani AA, Andalib S, Di Napoli M et al. Coronavirus Disease 2019 and Stroke: Clinical Manifestations and Pathophysiological Insights // J Stroke
Cerebrovasc Dis. – 2020. – №29(8). –S.104-941. doi: 10.1016/j.jstrokecerebrovasdis.2020.104941.
16 Böhm M, Frey N, Giannitsis E et al. Coronavirus disease 2019 (COVID-19) and its implications for cardiovascular care: expert document from the German
Cardiac Society and the World Heart Federation // Clin Res Cardiol. – 2020. – №27. – S.1-14.
17 Marisa D, Ferranti JF, Monteiro RA et al. SARS-CoV-2 in cardiac tissue of a child with COVID-19-
18 related multisystem inflammatory syndrome // Lancet Child Adolesc Health. –2020. – №4. –S.790-94.
19 Girerd N, Chapet N, Roubille C et al. Vaccination for Respiratory Infections in Patients with Heart
20 Failure // J. Clin. Med. – 2021. – №10. – S. 4311. doi:10.3390/jcm10194311.
21 Vardeny O, Kim K, Udell JA. INVESTED Committees and Investigators. Effect of High-Dose
22 Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary
23 Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial //
24 JAMA. – 2021. – №325(1). – S.39-49. doi: 10.1001/jama.2020.23649.
25 Yang J, Zheng Y, Gou X et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis International // Journal of Infectious
26 Diseases. – 2020. – №1.- S. 20-43.
27 Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin // Eur Heart J. – 2020. – №16.- S.101-
110.
28 Pelle MC, Zaffina I, Lucà S et al. Endothelial Dysfunction in COVID-19: Potential Mechanisms and Possible Therapeutic Options // Life (Basel). – 2022.
– №12(10).- S.1605. doi: 10.3390/life12101605.
29 Tavazzi G, Pellegrini C, Maurelli M et al. Myocardial localization of coronavirus in COVID-19
30 cardiogenic shock // Eur. J. Heart Fail. – 2020. – №4. – S. 911-915.
31 Arentz M, Yim E, Klaff L et al. Characteristics and Outcomes of 21 Critically Ill Patients With
32 COVID-19 in Washington State // JAMA. – 2020. – №323(16).- S.1612-1614.
33 doi:0.1001/jama.2020.4326.
34 Sardu C, Gambardella J, Morelli MB et al. Hypertension, thrombosis, kidney failure, and diabetes: is
35 COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence // J Clin Med. – 2020 . – №9(5). – S.1417.
36 Schiffrin EL, Flack J, Ito S et al. Hypertension and COVID-19 // Am J Hypertens. -2020. – №33. – S. 333-373.
37 Amraei R, Rahimi N. COVID-19, Renin-Angiotensin System and Endothelial Dysfunction // Cells. 2020. – №9(7). – S.1652. doi: 10.3390/cells9071652.
38 Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19)-United States, February 12- March 16, 2020 // MMWR Morb Mortal Wkly
Rep. – 2020. – №69(12).- S.343-346.
39 Bikdeli B, Madhavan MV, Jimenez D et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and
follow-up // J Am Coll Cardiol. – 2020. – №75(23). – S 2950-2973. doi: 10.1016/j.jacc.2020.04.031.
40 Sears SP, Getz TW, Austin CO. Incidence of sustained ventricular tachycardia in patients with prolonged QTc after the administration of azithromycin: a
retrospective study // Drugs Real World Outcome. – 2016.- №3. – S.99-105.
41 Huang C, Wang Y, Li X u X et al. Clinical features of patients infected with 2019 novel coronavirus
42 in Wuhan, China // Lancet. -2020. – № 395(10223).–S.497-506.doi:10.1016/S0140-6736 (20)30183-5.
43 Wang D, Hu B, Hu C, Zhu F et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China
// JAMA. -2020. – №323(11).- S.1061-1069. doi: 10.1001/jama.2020.1585.
44 Chu CM, Cheng VC, Hung IF et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings // Thorax. – 2004. – №59.
-.S.252-256.
45 Zhang M, Xie M, Li S et al. Electrophysiologic studies on the risks and potential mechanism underlying the proarrhythmic nature of azithromycin //
Cardiovasc. Toxicol. – 2017. – №17.- S.434-434.
46 Dolhnikoff M, Duarte-Neto AN, de Almeida Monteiro RA et al. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19 // J Thromb
Haemost. – 2020.- №18(6). –S. 1517-1519. doi: 10.1111/jth.14844.
47 Akhmerov A, Marban E. COVID-19 and the Heart. Circ // Circulation Research.- 2020. – №126 (10). –S. 1443–1455. doi: 10.1161/CIRCRESAHA.120.317055.
REFERENCES
48 Wiersinga W. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19) // JAMA. – 2020. – №324. – S.782-793.
49 Soumya RS, Unni TG, Raghu KG. Impact of COVID-19 on the Cardiovascular System: A Review of Available Reports // Cardiovasc Drugs Ther. – 2021.-
№35(3).- S.411-425. doi: 10.1007/s10557-020- 07073- y. Epub 2020 Sep 14.
50 Баздырев Е.Д. Коронавирусная инфекция — актуальная проблема XXI века // Комплексные проблемы сердечно-сосудистых заболеваний. – 2020.
– № 9(2).- S. 6-16.
51 Bazdirev ED. Coronavirus infection –actual problem of 21century // Complex problems of cardio-vascular diseases. – 2020. – №9(2). – S.6-16.
52 Khawaja SA, Mohan P, Jabbour R, et al. COVID-19 and its impact on the cardiovascular system // Open Heart. – 2021. – №8 (e001472) doi: 10.1136/
openhrt-2020-001472.
53 Groß S, Jahn C, Cushman S, Bär C, Thum T. SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: from basic science to
clinical implications // J Mol Cell Cardiol. – 2020. – №144.- S.47–53.
54 Mohammad M, Safavi-Naeini P, Scott D et al. Potential Effects of Coronaviruses on the
Cardiovascular System // JAMA Cardiol. – 2020. – №5(7). – S.831-840.
55 Bojkova D, Wagner JUG, Shumliakivska M, Aslan GS et al. SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes // Cardiovasc Res.
– 2020.- №116(14). –S.2207-2215. doi:10.1093/cvr/cvaa267.
56 Sharma A, Garcia G Jr, Wang Y et al. Human iPSC-Derived Cardiomyocytes Are Susceptible to SARS-CoV-2 Infection //Cell Rep Med.–2020. – №21(4).
– S.100052. doi:10.1016/j.xcrm.2020.100052.
57 Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients
with COVID-19 in Wuhan, China // JAMA Cardiol. – 2020.- №25. –S.44-58.
58 Chen C, Yan JT et al. Analysis of myocardial injury in patients with COVID19 and association between concomitant cardiovascular diseases and severity
of COVID-19 // Zhonghua Xin Xue Guan
59 Bing Za Zhi. – 2020 . – №48: S.1020-1058.
60 Bansal M. Cardiovascular disease and COVID-19 // Diabetes Metab Syndr. – 2020. – №14. –S.247-250.
61 Bonow RO, Fonarow GC, O’Gara PT, Yancy CW. Association of coronavirus disease 2019 (COVID-19) with myocardial injury and mortality // JAMA Cardiol.
– 2020. – №5(7). – S.751-753. doi:10.1001/jamacardio.2020.1105.
62 Divani AA, Andalib S, Di Napoli M et al. Coronavirus Disease 2019 and Stroke: Clinical Manifestations and Pathophysiological Insights // J Stroke
Cerebrovasc Dis. – 2020. – №29(8). –S.104-941. doi: 10.1016/j.jstrokecerebrovasdis.2020.104941.
63 Böhm M, Frey N, Giannitsis E et al. Coronavirus disease 2019 (COVID-19) and its implications for cardiovascular care: expert document from the German
Cardiac Society and the World Heart Federation // Clin Res Cardiol. – 2020. – №27. – S.1-14.
64 Marisa D, Ferranti JF, Monteiro RA et al. SARS-CoV-2 in cardiac tissue of a child with COVID-19-
65 related multisystem inflammatory syndrome // Lancet Child Adolesc Health. –2020. – №4. –S.790-94.
66 Girerd N, Chapet N, Roubille C et al. Vaccination for Respiratory Infections in Patients with Heart
67 Failure // J. Clin. Med. – 2021. – №10. – S. 4311. doi:10.3390/jcm10194311.
68 Vardeny O, Kim K, Udell JA. INVESTED Committees and Investigators. Effect of High-Dose
69 Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary
70 Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial //
71 JAMA. – 2021. – №325(1). – S.39-49. doi: 10.1001/jama.2020.23649.
72 Yang J, Zheng Y, Gou X et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis,
International // Journal of Infectious
73 Diseases. – 2020. – №1.- S. 20-43.
74 Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin // Eur Heart J. – 2020. – №16.- S.101-
110.
75 Pelle MC, Zaffina I, Lucà S et al. Endothelial Dysfunction in COVID-19: Potential Mechanisms and Possible Therapeutic Options // Life (Basel). – 2022.
– №12(10).- S.1605. doi: 10.3390/life12101605.
76 Tavazzi G, Pellegrini C, Maurelli M et al. Myocardial localization of coronavirus in COVID-19
77 cardiogenic shock // Eur. J. Heart Fail. – 2020. – №4. – S. 911-915.
78 Arentz M, Yim E, Klaff L et al. Characteristics and Outcomes of 21 Critically Ill Patients With
79 COVID-19 in Washington State // JAMA. – 2020. – №323(16).- S.1612-1614.
80 doi:0.1001/jama.2020.4326.
81 Sardu C, Gambardella J, Morelli MB et al. Hypertension, thrombosis, kidney failure, and diabetes: is
82 COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence // J Clin Med. – 2020 . – №9(5). – S.1417.
83 Schiffrin EL, Flack J, Ito S et al. Hypertension and COVID-19 // Am J Hypertens. -2020. – №33. – S. 333-373.
84 Amraei R, Rahimi N. COVID-19, Renin-Angiotensin System and Endothelial Dysfunction // Cells. 2020. – №9(7). – S.1652. doi: 10.3390/cells9071652.
85 Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19)-United States, February 12- March 16, 2020 // MMWR Morb Mortal Wkly
Rep. – 2020. – №69(12).- S.343-346.
86 Bikdeli B, Madhavan MV, Jimenez D et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and
follow-up // J Am Coll Cardiol. – 2020. – №75(23). – S 2950-2973. doi: 10.1016/j.jacc.2020.04.031.
87 Sears SP, Getz TW, Austin CO. Incidence of sustained ventricular tachycardia in patients with prolonged QTc after the administration of azithromycin: a
retrospective study // Drugs Real World Outcome. – 2016.- №3. – S.99-105.
88 Huang C, Wang Y, Li X u X et al. Clinical features of patients infected with 2019 novel coronavirus
89 in Wuhan, China // Lancet. -2020. – № 395(10223).–S.497-506.doi:10.1016/S0140-6736 (20)30183-5.
90 Wang D, Hu B, Hu C, Zhu F et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China
// JAMA. -2020. – №323(11).- S.1061-1069. doi: 10.1001/jama.2020.1585.
91 Chu CM, Cheng VC, Hung IF et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings // Thorax. – 2004. – №59.
-.S.252-256.
92 Zhang M, Xie M, Li S et al. Electrophysiologic studies on the risks and potential mechanism underlying the proarrhythmic nature of azithromycin //
Cardiovasc. Toxicol. – 2017. – №17.- S.434-434.
93 Dolhnikoff M, Duarte-Neto AN, de Almeida Monteiro RA et al. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19 // J Thromb
Haemost. – 2020.- №18(6). –S. 1517-1519. doi: 10.1111/jth.14844.
94 Akhmerov A, Marban E. COVID-19 and the Heart. Circ // Circulation Research.- 2020. – №126 (10). –S. 1443–1455. doi: 10.1161/CIRCRESAHA.120.317055.
